web response system. Randomization was stratified according to concomitant SU use at screening and baseline HbA1c stratum(/H110219.0% or /H113509.0%). Patients randomized to ExQW received sc 2-mg doses once weekly for 24 wk. Patients randomized toExBID received 5 /H9262g sc twice daily (BID) for 4 wk followed by 10/H9262g sc BID for 20 wk, consistent with recommended dosing for ExBID (19). Patients self-administered study medication aftertraining by study site personnel. Sponsor personnel remainedblinded to HbA1c and FPG data throughout treatment. Study end points The study was designed to compare the effects of ExQW and